Catalog No.
Product Name
Application
Product Information
Citations
-
Nucleoside Analog
6-((Bis(4-methoxyphenyl)(phenyl)methyl)amino)hexyl (2-cyanoethyl) diisopropylphosphoramidite is a nucleoside analog that serves as an essential monomer for nucleic acid synthesis. This compound facilitates the incorporation of modified nucleotides into oligonucleotides, enabling the exploration of diverse biochemical and genetic applications. Its unique chemical structure enhances stability and provides opportunities for creating novel therapeutic agents and diagnostic tools. -
Nucleoside Analog
DMTr-2'-dA(Bz)-3'-S-CE-phosphoramidite is a nucleoside analog designed for use in nucleic acid synthesis. This phosphoramidite monomer enables the incorporation of modified adenine into oligonucleotides, providing utility in the development of nucleotide-based therapeutics and research applications. Its unique structure enhances stability and facilitates the production of customized DNA and RNA sequences for various biochemical studies. -
Nucleoside Analog
UTP(αB) is a nucleoside analog primarily utilized in nucleic acid synthesis. This compound serves as a building block for RNA transcription and other molecular biology applications. Its unique structure allows for enhanced stability and incorporation into RNA molecules, making it valuable for research in genetic engineering and synthetic biology. -
Nucleoside Analog
N4-Me-dCTP is a nucleoside analog that serves as a versatile monomeric building block for nucleic acid synthesis. Its incorporation into DNA or RNA can facilitate studies on DNA replication, modification, and metabolic processes. This compound is valuable in research applications that require the synthesis of modified oligonucleotides for therapeutic and diagnostic purposes. -
Nucleoside Analog
6'-O-DMTr-2'-O-Me-5'-homo-A(Bz)-3'-CE-phosphoramidite is a nucleoside analog designed as a monomeric raw material for the synthesis of nucleic acids. This compound facilitates the incorporation of modified nucleotides into oligonucleotide sequences, enhancing stability and cellular uptake. Its applications encompass various areas of molecular biology and biochemistry, including the development of therapeutics and probes for RNA and DNA studies. -
Nucleoside Analog
2′-OMe-UMP is a nucleoside analog that serves as a building block in the synthesis of oligonucleotides. It alters RNA properties, enhancing the stability and binding affinity of synthesized strands. This compound is commonly utilized in molecular biology to design probes and therapeutics targeting RNA molecules. -
Nucleoside Analog
3'-O-TBDMS-2'-dG(iBu) is a nucleoside analog that serves as a crucial monomer for nucleic acid synthesis. This compound is utilized in various biochemical applications, including the development of oligonucleotides and the study of nucleic acid interactions. Its unique chemical properties enhance the stability and functionality of nucleic acids in research settings. -
Nucleoside Analog
3'-Azidomethyl-dGTP is a nucleoside analog that acts as a substrate for nucleic acid synthesis. This compound is utilized in various applications, including the incorporation of modified nucleotides in oligonucleotides and the study of nucleic acid interactions. Its unique azido group allows for bioorthogonal reactions, making it valuable for advanced bioconjugation techniques in molecular biology research. -
Nucleoside Analog
2'-O-MOE-UTP is a nucleoside analog utilized in the synthesis of modified oligonucleotides. It enhances RNA stability and is primarily known for its ability to increase resistance to nuclease degradation. This compound is widely used in the development of RNA therapeutics, probes, and in applications such as PCR and gene expression studies. -
Nucleoside Analog
DMTr-2'-O-C6-rU-3'-CE-phosphoramidite is a nucleoside analog designed for use in nucleic acid synthesis. This phosphoramidite serves as a versatile building block in the production of oligonucleotides, facilitating the incorporation of modified bases into nucleic acid sequences. Its unique structure enhances the stability and versatility of resultant nucleic acids, making it suitable for a variety of research applications, including functional studies and therapeutic development. -
Nucleoside Analog
TPT3TP is a nucleoside analog that serves as a monomeric building block for the synthesis of nucleic acids. This compound is useful in biochemical research applications, including the study of nucleic acid structure and function. Its unique properties enable the exploration of novel nucleic acid sequences and potential therapeutic developments. -
Nucleoside Analog
DMTr-dI-3'-(D)-PSM-phosphoramidite is a nucleoside analog that serves as a key monomer for the synthesis of oligonucleotides. Its incorporation into nucleic acid sequences enables researchers to investigate structural and functional properties of nucleic acids. This compound is particularly useful in the development of modified oligonucleotides for various applications in gene therapy, antisense technology, and molecular biology research. -
Nucleoside Analog
5'-OH-(2'OMe-G)pG is a nucleoside analog that serves as a monomeric building block for nucleic acid synthesis. Its modified structure enhances stability and increases resistance to nucleases. This reagent is particularly useful in the development of oligonucleotides for research applications in gene therapy, antisense oligonucleotides, and RNA interference studies. -
Nucleoside Analog
DMTr-2'-ara-F-dG(dmf)-3'-CE-phosphoramidite is a modified nucleoside analog designed for use in nucleic acid synthesis. This reagent serves as a key building block for generating oligonucleotides with specific functionalities. Its incorporation facilitates the study of nucleic acid structure and function, making it valuable in applications such as gene expression analysis, antisense oligonucleotide development, and nucleic acid-based therapeutics. -
Nucleoside Analog
2'-Deoxy-3',5'-CDP (pdCp) is a nucleoside analog utilized in nucleic acid synthesis. As a key monomer, it plays a vital role in the construction of DNA strands during various molecular biology applications. Its incorporation into oligonucleotides can enhance studies in genetic engineering, gene expression analysis, and therapeutic development. -
Nucleoside Analog
2'-OMe-uTP is a nucleoside analog that serves as a crucial monomer for nucleic acid synthesis. Its modification enhances the stability and bioavailability of RNA molecules, making it valuable for research applications in RNA biology, therapeutic development, and the study of gene expression. This compound is instrumental in the synthesis of modified RNA, allowing for innovative approaches in the design of RNA-based therapeutics and molecular probes. -
Nucleoside Analog
3'-O-Phthalimido-2'-deoxythymidine is a nucleoside analog that serves as a monomeric precursor for nucleic acid synthesis. This compound is primarily utilized in research applications related to DNA and RNA assembly, enabling the exploration of oligonucleotide properties and functions. Its incorporation into synthetic pathways enhances the study of genetic mechanisms and therapeutic development. -
Nucleoside Antimetabolite/Analog
1-Acetyl-3-o-toluyl-5-fluorouracil is a nucleoside antimetabolite that serves as a 5-fluorouracil analog. This compound exhibits significant antitumor activity, making it a valuable tool in cancer research. It is primarily utilized to study cellular mechanisms of chemoresistance and to evaluate therapeutic strategies for various malignancies. -
PARG Inhibitor
PDD00017272 is a potent inhibitor of poly(ADP-ribose) glycohydrolase (PARG) with an EC50 of 4.8 nM. By inhibiting PARG activity, this compound promotes the accumulation of poly(ADP-ribose) (pADPr) on chromatin, thereby disrupting DNA damage repair and replication processes, leading to PARP1/2-dependent cytotoxicity. PDD00017272 is particularly valuable for research applications involving cancer models with DNA repair deficiencies, such as those characterized by BRCA mutations, and demonstrates enhanced efficacy in tumor cells exhibiting lower PARG expression. -
PARG Inhibitor
PDD00017238 is a potent inhibitor of Poly(ADP-ribose) Glycohydrolase (PARG), demonstrating EC50 values of 40 nM in biochemical assays and 55 nM in cellular assays. This compound effectively disrupts the enzymatic activity of PARG, leading to the accumulation of poly(ADP-ribose) chains and influencing DNA repair mechanisms. PDD00017238 is useful for studying the role of PARG in cellular processes, particularly in the context of DNA damage response and potential therapeutic strategies in oncology. -
PARG Inhibitor
PDD00031705 is a benzimidazolone-based inhibitor targeting poly (ADP-ribose) glycohydrolase (PARG). This compound exhibits potential in regulating poly (ADP-ribose) metabolism, which plays a critical role in DNA damage repair and cell signaling. PDD00031705 is useful in research applications focused on understanding the physiological and pathological roles of PARG in cellular processes and its implications in cancer biology. -
PARG Inhibitor
COH34 analog 1 is an oxidized derivative of the potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor, COH34. This compound specifically targets PARG, leading to the inhibition of poly(ADP-ribose) metabolism. Its role in PARG inhibition makes it a valuable tool for studying cellular processes involved in DNA repair, cellular stress responses, and other related pathways in chemical biology and therapeutic research. -
PARG Inhibitor
PARG-IN-7 is a potent inhibitor of Poly ADP-ribose glycohydrolase (PARG), exhibiting an IC50 of less than 0.1 μM. This compound significantly reduces cell viability in HCC1806 cells with XRCC1 knockdown, demonstrating an IC50 of less than 1 μM. PARG-IN-7 is a valuable tool for cancer research, particularly in studies investigating the role of PARP-related pathways in tumor biology. -
PARG Inhibitor
PDD00031704 is an inhibitor of poly (ADP-ribose) glycohydrolase (PARG), demonstrated to have an IC50 value greater than 60 µM. It plays a crucial role in the regulation of ADP-ribosylation, impacting cellular processes such as DNA repair and apoptosis. This compound is valuable for research applications focused on cancer biology, cellular stress responses, and modulation of DNA damage pathways. -
PARG Inhibitor
FORX-428 is a selective and orally bioavailable inhibitor of Poly (ADP-ribose) glycohydrolase (PARG), which targets the catalytic domain of human PARG to effectively inhibit its enzymatic activity. By promoting the accumulation of PAR chains, FORX-428 activates DNA damage response pathways and replication stress responses. This compound demonstrates selective antiproliferative effects across a range of cancer cell lines, including those derived from breast, ovarian, and gastric cancers, making it a valuable tool for cancer research and therapeutic studies. -
PARP-1 Inhibitor
PARP-1-IN-32 is a potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1). This compound is utilized in cancer research to investigate the mechanisms of DNA repair and cellular response to genotoxic stress. Its ability to selectively inhibit PARP-1 makes it a valuable tool for studying the role of this enzyme in tumor biology and therapeutic resistance. -
SIRT6 Inhibitor
SIRT6-IN-6 is a selective inhibitor of SIRT6, demonstrating a potent IC50 of 4.93 μM and a Ki of approximately 10 μM. This compound shows significant selectivity against other histone deacetylases, including SIRT1-3 and HDAC1-11. Research findings indicate that SIRT6-IN-6 effectively elevates the expression of the glucose transporter GLUT-1, which contributes to the reduction of blood glucose levels in mouse models of type 2 diabetes. This reagent is valuable for studies focused on the mechanistic pathways associated with type 2 diabetes and metabolic regulation. -
Sirtuin Inhibitor
MC3482 is a selective inhibitor of sirtuin 5 (SIRT5), known for its role in mitochondrial metabolism and deacylation processes. This compound effectively modulates SIRT5 activity, making it valuable for studies examining the implications of SIRT5 in cellular energy regulation and metabolic disorders. Its use in research can contribute to understanding SIRT5's role in various physiological and pathological conditions, including cancer and neurodegeneration. -
SIRT5 Inhibitor
MC3138 is a selective SIRT5 inhibitor, demonstrating notable antitumor activity in human pancreatic ductal adenocarcinoma (PDAC) cells, with IC50 values ranging from 25.4 to 236.9 μM. In preclinical studies, MC3138 enhances the efficacy of Gemcitabine, significantly inhibiting tumor growth in murine models. This compound is valuable for research into targeted cancer therapies and the modulation of metabolic pathways related to SIRT5 activity. -
SIRT3 Activator
2-APQC is a selective activator of Sirtuin-3 (SIRT3), exhibiting an affinity of Kd=2.756 μM. This compound enhances mitochondrial proline metabolism through the SIRT3-PYCR1 axis and mitigates ROS-induced cytotoxicity by inhibiting the mTOR-p70S6K, JNK, and TGF-β/Smad3 signaling pathways. Additionally, 2-APQC activates the AMPK-Parkin axis, providing a protective effect against myocardial hypertrophy and fibrosis, making it a valuable tool for researching heart failure and related cardiac dysfunctions. -
Sirtuin Activator
ADTL-SA1215 is a novel small-molecule activator of SIRT3, targeting the regulation of autophagy pathways. This compound has demonstrated potential in inducing autophagy in triple-negative breast cancer cells, presenting opportunities for cancer research and therapeutic development. Its specificity for SIRT3 makes it an essential tool for studying the role of sirtuins in cellular metabolism and cancer progression. -
SIRT5 Inhibitor
Et-29 is a potent inhibitor of SIRT5, with a reported Ki value of 40 nM, demonstrating selectivity for this target. By modulating the activity of SIRT5, Et-29 plays a significant role in the study of metabolic processes and post-translational modifications. This reagent is ideal for research applications focused on the regulation of cellular metabolism and potential therapeutic strategies in metabolic diseases. -
SIRT6 Inhibitor
SIRT6-IN-2 is a selective and competitive inhibitor of SIRT6, exhibiting an IC50 of 34 μM. This compound enhances the acetylation of H3K9 and promotes glucose uptake in cultured cells. Additionally, SIRT6-IN-2 demonstrates the ability to reduce T cell proliferation, showcasing its immunosuppressive properties and potential chemosensitizing effects. Research applications include the study of metabolic regulation and immune response modulation. -
SIRT Inhibitor
SIRT-IN-3 is a selective inhibitor of SIRT1 with an IC50 of 17 μM. It demonstrates approximately 4-fold selectivity over SIRT2 and 14-fold selectivity over SIRT3, exhibiting IC50 values of 74 μM and 235 μM, respectively, for these isoforms. This compound is valuable for research applications investigating the role of SIRT1 in cellular processes, including aging, metabolism, and gene regulation. -
SIRT5 Inhibitor
SIRT5 Inhibitor 3 is a potent and competitive inhibitor of SIRT5, exhibiting an IC50 value of 5.9 μM. This compound effectively inhibits the desuccinylation activity of SIRT5, making it a valuable tool for studying the enzyme's role in various biological processes. SIRT5 Inhibitor 3 is applicable in research focused on cancer and neurodegenerative diseases, providing insights into potential therapeutic strategies. -
SIRT3 Activator
SIRT3 Activator 2 is a selective activator of the SIRT3 enzyme. This compound enhances the thermal stability of SIRT3 in SH-SY5Y cells through direct binding, facilitating the clearance of α-synuclein in a SIRT3-dependent manner. In vivo studies demonstrate that SIRT3 Activator 2 improves motor function in Parkinson’s disease models and prevents the loss of dopamine neurons in the substantia nigra in a dose-dependent fashion, making it a valuable tool for research into neurodegenerative disorders. -
Sirt1 Activator
Lumbokinase is a Sirt1 activator that plays a crucial role in mitigating myocardial ischemia-reperfusion (I-R) injury. By enhancing Sirt1 signaling, it promotes autophagic flux while simultaneously reducing oxidative damage, inflammation, and apoptosis associated with I-R events. This compound is valuable for research applications focused on cardiac protection, autophagy modulation, and the underlying mechanisms of ischemic injury. -
Sirtuin Modulator
Sirtuin Modulator 1 is a selective modulator of SIRT1, a member of the sirtuin family of NAD+-dependent deacetylases. With an effective concentration of less than 1 μM, it demonstrates significant biological activity in the regulation of cellular aging and metabolism. This reagent holds potential for research applications in studying age-related diseases, metabolic disorders, and the mechanisms of epigenetic regulation mediated by sirtuins. -
SIRT1 Inhibitor
SIRT1-IN-4 is a selective SIRT1 inhibitor that demonstrates an IC50 of 10.04 μM. This compound is utilized in research focused on cancer biology, providing valuable insights into the role of SIRT1 in tumorigenesis and potential therapeutic approaches. Further studies may explore its utility in modulating cellular processes regulated by SIRT1. -
SIRT1 Activator
E1231 is a potent activator of Sirtuin 1 (SIRT1), exhibiting an EC50 of 0.83 μM. This compound enhances cholesterol and lipid metabolism by interacting with SIRT1 (KD = 9.61 μM) and promoting the deacetylation of liver X receptor-alpha (LXRα), which subsequently increases the expression of ATP-binding cassette transporter A1 (ABCA1). Additionally, E1231 has demonstrated efficacy in reducing atherosclerotic plaque development in ApoE-/- mouse models, making it a valuable tool for research into lipid disorders and related diseases. -
SIRT1 Inhibitor
(S)-Selisistat is a selective inhibitor of SIRT1, demonstrating an IC50 value of 98 nM. This compound effectively modulates the activity of the sirtuin family of proteins, which are implicated in various cellular processes, including metabolism and aging. (S)-Selisistat is valuable for research exploring the role of SIRT1 in age-related diseases and metabolic disorders, making it a crucial tool for investigating therapeutic strategies in these areas. -
SIRT3 Inhibitor
SIRT3-IN-1 is a potent Sirtuin 3 (SIRT3) inhibitor with an IC50 value of 0.043 μM. This compound selectively inhibits SIRT3, making it a valuable tool for studying the role of SIRT3 in acute myeloid leukemia (AML) and other related conditions. Its specific action on SIRT3 allows for targeted investigations into cellular metabolism, oxidative stress response, and potential therapeutic strategies in AML research. -
SIRT7 Inhibitor
YZL-51N is a selective inhibitor of SIRT7, with an IC50 value of 12.71 μM. By occupying the NAD+ binding pocket, YZL-51N inhibits SIRT7 enzyme activity, thereby compromising DNA damage repair mechanisms and reducing cancer cell viability. Its demonstrated anti-tumor activity makes YZL-51N a valuable tool for cancer research applications. -
SIRT1 Inhibitor
SIRT1-IN-3 is a selective inhibitor of SIRT1, exhibiting an IC50 value of 4.2 μM. This compound effectively modulates SIRT1 activity, making it a valuable tool for studies investigating the role of SIRT1 in various biological processes. Research applications include the exploration of SIRT1's involvement in metabolism, aging, and stress response pathways. -
Sirtuin
(R)-Selisistat (R)-EX-527 is a selective inhibitor of SIRT1, exhibiting an IC50 of 98 nM. This compound primarily targets the Sirtuin family of proteins, known to play critical roles in cellular regulation, metabolism, and aging. Research applications include the investigation of SIRT1's involvement in neurodegenerative diseases, metabolic disorders, and cancer biology. (R)-Selisistat serves as a valuable tool for studying the modulation of SIRT1 activity in various biological contexts. -
SIRT1 Inhibitor
SIRT1-IN-2 is a potent and selective inhibitor of SIRT1 (silent information regulator 1), demonstrating an IC50 value of 1.6 μM. This compound plays a critical role in research focused on understanding the regulation of cellular metabolism, aging, and stress response pathways. Its specific inhibition of SIRT1 makes it a valuable tool for studying related biological processes and therapeutic interventions. -
Sirt2 Inhibitor
Sirt2-IN-2 is a selective inhibitor of the Sirtuin 2 (Sirt2) enzyme, exhibiting an IC50 of 0.118 μM. This compound is instrumental in research aimed at studying the role of Sirt2 in cellular processes and its implications in neurodegenerative diseases. Its use facilitates investigations into the potential therapeutic effects of Sirt2 modulation. -
Sirtuin Modulator
Sirtuin modulator 6 is a selective modulator of sirtuin proteins, known for its role in enhancing cellular longevity. This compound exhibits potential therapeutic effects in the context of metabolic disorders such as diabetes and obesity, as well as neurodegenerative and cardiovascular diseases. Its mechanism of action supports research into the modulation of sirtuin pathways, providing insights into various age-related health conditions. -
Sirtuin Modulator
Sirtuin modulator 8 is an effective activator of sirtuin proteins, demonstrating the capacity to enhance sirtuin activity. This compound significantly reduces the expression of monocyte chemoattractant protein-1 (MCP-1) while increasing fibroblast growth factor 21 (FGF21) levels. By regulating genes associated with inflammation and metabolism, Sirtuin modulator 8 is a valuable tool for researching metabolic disorders such as diabetes and obesity, as well as inflammatory diseases. -
Sirt2 inhibitor
SirReal-1 is a selective inhibitor of SIRT2, with an IC50 of 3.7 μM. This compound is utilized in research to investigate the biological role of SIRT2 in various cellular processes and its potential implications in cancer and neurodegenerative diseases. SirReal-1 serves as a valuable tool for elucidating the mechanisms of SIRT2-related signaling pathways.
